Discovering next generation antibody-based therapeutics addressing challenging targets for the treatment of cancer.
Our Company
QLSF Biotherapeutics is an innovative immuno-oncology startup company in South San Francisco. Our research and development are focused on a diversified oncology portfolio, with strong financial and clinical development support from a leading pharmaceutical company.
Fully integrated research and development leveraging our interdisciplinary expertise
Our Approach
Rational design to build modular and customizable molecules
Our Science
Tumor biology driven therapeutic strategy and target selection
Our candidates are designed to target both the adaptive and innate immune systems, with complementary mechanisms of action for broad anti-tumor activity.
Myeloid Rich
Biology: Abundant myeloid cells in tumor
Strategy: Tumor cell phagocytosis and antigen presentation
Candidates:
- QL401 PD-L1 x CD47, Phase 1
- Novel first-in-class bispecific, Discovery
Immunologically Cold
Biology: T cells absent in tumor or periphery
Strategy: Redirect and activate T cells
Candidates:
Next Generation T Cell Engagers
Inflamed​
Biology: Abundant T cells in tumor but inactive or exhausted
Strategy: Reactivate and invigorate T cells
Candidates:
- QL301 PD-L1 x 4-1BB, Phase 1/2
- QL415 PD-L1 x IL-15, Phase 1
- QL425 T cell targeted cytokine, Preclinical
Management
Shihao Chen, PhD
CEO, Co-Founder
Yonglei Shang, MD
SVP, Antibody Discovery
Greg Naeve, PhD
Chief Business Officer
Advisors
Alan Wahl, PhD
Chief Scientific Advisor
Premal Patel, MD, PhD
Chief Medical Advisor
Pamela Garzone, PhD
